CytomX Therapeutics (NASDAQ:CTMX) Sets New 12-Month High – Here’s What Happened

CytomX Therapeutics, Inc. (NASDAQ:CTMX)’s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $7.74 and last traded at $7.28, with a volume of 57367736 shares trading hands. The stock had previously closed at $4.68.

CytomX Therapeutics News Summary

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Phase 1 dose‑expansion data for Varsetatug Masetecan showed confirmed response rates (32% at 10 mg/kg Q3W; 20% at 8.6 mg/kg Q3W) and estimated PFS ~7 months, supporting the drug’s potential in late‑line colorectal cancer; company is targeting mid‑year FDA interactions to discuss a possible registrational trial. CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
• Positive Sentiment: The company announced additional clinical plans (combination and chemo studies) and a conference call to discuss 2025 results and the Varseta data, which supports near‑term development catalysts. CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Company filed Q4 press materials and a slide deck; management held a conference call to review results and the clinical update (useful for investors who want detail on timelines and next steps). View Press Release / Slide Deck
• Neutral Sentiment: Analyst previews and model updates were published ahead of the print, so expect some revision in sell‑side forecasts as analysts digest the clinical readouts versus the financial miss. CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts
• Negative Sentiment: Q4 results missed expectations: GAAP loss of $0.22 per share vs. consensus loss of $0.08 and revenue of $0.66M versus estimates near $7.3M — the financial miss could pressure near‑term fundamentals and raise questions about funding/timing if development costs rise. CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates

Analyst Upgrades and Downgrades

CTMX has been the subject of several recent analyst reports. Piper Sandler boosted their price target on shares of CytomX Therapeutics from $6.50 to $10.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. Guggenheim reissued a “buy” rating and set a $10.00 target price on shares of CytomX Therapeutics in a research note on Monday, March 9th. Barclays upped their price target on shares of CytomX Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 4th. Finally, Cantor Fitzgerald raised their price target on shares of CytomX Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a research note on Wednesday, February 4th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $9.00.

CytomX Therapeutics Stock Performance

The company has a market cap of $1.31 billion, a price-to-earnings ratio of 19.45 and a beta of 2.44. The firm’s 50 day simple moving average is $5.19 and its 200-day simple moving average is $4.04.

Institutional Trading of CytomX Therapeutics

Large investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. acquired a new stake in CytomX Therapeutics in the 1st quarter valued at about $39,000. Woodline Partners LP purchased a new stake in shares of CytomX Therapeutics in the first quarter valued at approximately $1,054,000. Geode Capital Management LLC grew its position in shares of CytomX Therapeutics by 103.4% in the second quarter. Geode Capital Management LLC now owns 1,745,176 shares of the biotechnology company’s stock valued at $3,963,000 after purchasing an additional 887,218 shares in the last quarter. Franklin Resources Inc. acquired a new stake in shares of CytomX Therapeutics in the second quarter valued at approximately $13,096,000. Finally, XTX Topco Ltd acquired a new stake in shares of CytomX Therapeutics in the second quarter valued at approximately $277,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.